Catalent has entered an agreement with Triphase Accelerator Corp., a company that acquires and develops cancer therapies, under which Triphase will obtain worldwide rights to further develop Catalent’s CD22-4AP Antibody-Drug Conjugate (ADC). The drug was developed by Catalent’s subsidiary, Redwood Bioscience, Inc., using its SMARTag technology platform. Catalent will receive an upfront payment and potential development and commercial milestones, plus royalties on product sales. Triphase will ...